Mazapertine

Mazapertine is a atypical antipsychotic that is currently under development. It is a dopamine receptor partial agonist, with selectivity for the D2, D3, and D4 subtypes.

Pharmacology

Mazapertine acts as a partial agonist at dopamine receptors, specifically the D2, D3, and D4 subtypes. This means that it can both activate these receptors and block them, depending on the circumstances. This is in contrast to full agonists, which only activate receptors, and antagonists, which only block them.

Development

Mazapertine is currently under development as a potential treatment for schizophrenia and other psychotic disorders. It is being developed by the pharmaceutical company Pfizer.

Clinical Trials

As of now, Mazapertine has undergone several phases of clinical trials. These trials are designed to test the safety and efficacy of the drug in treating schizophrenia and other psychotic disorders. The results of these trials are not yet available.

See Also

• Atypical antipsychotic
• Dopamine receptor
• Schizophrenia
• Psychotic disorders

Mazapertine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski